Welcome and Chair Remarks
A. Kotsakis, F. Koinis
Chairs: N. Tsoukalas, I. Samaras
14.00-14.20 Presenter 1 Α. Kokkalis
abstracts 1500: Outcomes of COVID-19 in cancer patients: Report from the National COVID Cohort Collaborative (N3C)
abstract 12012: Barriers and Facilitators of Geriatric Assessment Implementation in daily Oncology practice: A qualitative Study Applying a Theoretical Implementation Framework
14.20-14.45 Presenter 2 G. Douganiotis
Abstract 12020: The comparative effectiveness of direct oral anti-coagulants and low molecular weight heparins for prevention of recurrent venous thromboembolism in cancer: The CANVAS pragmatic randomized trial
Abstract 1506: The future of tele-oncology: Trends and disparities in telehealth and secure message utilization in the COVID-19 era
Abstract 6507: Mobile low-dose computerized tomography (LDCT): Three-year follow up of solution for early diagnosis of lung cancer in under-served populations
14.45-15.05 Presenter 3 D. Papageorgiou
Αbstract 1005: Treatment-related side effects and views about dosage assessment to sustain quality of life: Results of an advocate-led survey of patients with metastatic breast cancer (MBC)
Abstract 3014: Racial and ethnic disparities among participants in precision oncology clinical studies
Abstract 12010: The effects of geriatric assessment on oncologist-patient communication regarding functional status and physical performance in older adults with cancer: A secondary analysis of a 541-subject nationwide URCC NCORP (NCI Community Oncology Research Program) cluster randomized trial
15.05-15.20 Discussion
Chairs: E. Saloustros, P. Makrythanasis
15.20-15.45 Presenter 4 Ε. Fountzila
Αbstract 10501: Nearly half of TP53 variants are misattributed to Li-Fraumeni syndrome: A clinical evaluation of individuals with TP53 variants detected by hereditary cancer panel assays on blood or saliva
Αbstract 10504: Underdiagnosis of germline genetic prostate cancer: Are genetic testing guidelines an aid or an impediment?
Αbstract 10516: Early age of onset and broad cancer spectrum persist in MSH6 and PMS2-associated Lynch syndrome
15.45-16.00 Discussant/Comments G. Lypas
Coffee Break
Chairs: G. Rigakos, Ch. Kosmas
16.15-16.35 Presenter 1 A. Tsiara
Αbstract 10009: Oral selpercatinib in pediatric patients (pts) with advanced RET-altered solid or primary CNS tumors: Preliminary results from the phase 1/2 LIBRETTO-121 trial
Abstract 2013: Long-term results of the GEINO 140 TRIAL: randomizing patients to stop or to continue temozolomide until 12 cycles
16.35-16.55 Presenter 2 T. Koukaki
Αbstract 2002: Efficacy and safety of larotrectinib in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system tumors
16.55-17.10 Discussant Ch. Emmanouilidis
Chairs: O. Tsitsilonis, K. Baxevanis
Checkpoint Inhibitor-Based Therapies: New ImmunoOncology Targets and Resistance Mechanisms
F. Koinis
Chairs: A. Argyris, A. Kotsakis
17.40-18.00 Presenter 1 P. Katsaounis
Αbstracts LBA2: JUPITER-02: Randomized, double-blind, phase 3 study of toripalimab or placebo plus
gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC)
Αbstract 6000: Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase III trial
18.00-18.20 Presenter 2 E. Eleftherakis-Papaiakovou
Αbstract 6001: Cabozantinib versus placebo in patients with radioiodine-refractory differentiated
thyroid cancer who have progressed after prior VEGFR-targeted therapy: Results from the phase 3 COSMIC-311 trial
Αbstract 6003: Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial
18.20-18.35 Discussant A. Argyris
Chairs: N. Xenidis, F. Koinis
18.35-18.55 Presenter 1 E. Kontopodis
Αbstract 2501: Phase II evaluation of the triple combination of PDS0101, M9241, and bintrafusp alfa
in patients with HPV 16 positive malignancies
Αbstract 3004: MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors
18.55-19.20 Presenter 2 G. Fotopoulos
Αbstract 2506: Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs
Αbstract 3006: First-in-human phase 1/2 study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers
Αbstract 3007: A phase Ib trial of belvarafenib in combination with cobimetinib in patients with advanced solid tumors: Interim results of dose-escalation and patients with NRAS-mutant melanoma of dose-expansion
19.20-19.30 Discussion
Chairs: F. Zagouri, D. Tryfonopoulos
19.30-19.50 Presenter 1 K. Rapti
Αbstract 503: De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel
weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results
Αbstract 1003: Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial
19.50-20.10 Presenter 2 R. Zakopoulou
Abstract 500: Outcome of patients with an ultralow risk 70-gene signature in the MINDA; CT trial
Abstract 501: Breast Cancer Index (BCI) and Prediction of Benefit from Extended Aromatase Inhibitor (AI) Therapy (tx) in HR+ Breast Cancer: NRG Oncology/NSABP B-42
20.10-20.35 Presenter 3 E. Papadimitraki
Abstract 1002: Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study
Abstract 12003: Prospective validation of genetic predictors of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) in a racially diverse cohort: Results from ECOG-ACRIN E1Z11
Abstract LBA1: OlympiA: A phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer
20.35-21.00 Discussant A. Matikas
Chairs: P. Papakostas, A. Boutis
09.00-09.20 Presenter 1 Ch. Avgerinou
Abstract 4003: Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction
cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): expanded efficacy and safety analyses from CheckMate 577
Abstract 4006: Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV)
for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): Multicenter comparative randomized phase 2b study (NIFTY)
09.20-09.40 Presenter 2 A. Markou
Abstract 3500: Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer
Abstract LBA 4001: Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus
chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study
09.40-10.00 Discussant V. Papadopoulos
Chairs: Z. Saridaki, Ch. Panopoulos
10.00-10.20 Presenter 1 E. Chantzara
Abstract 3504: Oral maintenance capecitabine versus active monitoring for patients with metastatic
colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial
Abstract 3507: The TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer
10.20-10.40 Presenter 2 O. Tsavaris
Abstract 3505: Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01)
Abstract 4006: Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV)
for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): Multicenter comparative randomized phase 2b study (NIFTY)
10.40-11.00 Discussant G. Papaxoinis
Coffee Break
Chairs: M. Liontos, I. Mountzios
Expanding the Druggable Universe F.I. Dimitrakopoulos
Chairs: D. Bafaloukos, K. Kalbakis
11.45-12.05 Presenter 1 J. Duran-Moreno
Abstract 9502: Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma
Abstract 9500: Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma
12.05-12.25 Presenter 2 G. Assi
Abstract 9503: Relatlimab (RELA) + nivolumab (NIVO) versus NIVO in first-line advanced melanoma:
Primary phase 3 results from RELATIVITY-047 (CA224-047)
Abstract 9505: Lifileucel (LN-144), a Cryopreserved Autologous Tumor Infiltrating Lymphocyte (TIL)
Therapy in Patients with Advanced Melanoma: Evaluation of Impact of Prior Anti-PD-1 Therapy
12.25-12.45 Discussant A. Laskarakis
Chairs: A. Kotsakis, A. Stribakos
Pancreatic Cancer - Challenges and Future Directions Α. Boutis
Light Lunch
Chairs: I. Boukovinas, A. Koumarianou
13.45-14.05 Presenter 1 S. Kokkali
Abstract 11502: Treatment delays are associated with an unfavorable outcome in patients with localized Ewing sarcoma: A retrospective analysis of data from the GPOH Euro-E.W.I.N.G.99 trial
Abstract 11504: SPEARHEAD-1: A phase 2 trial of afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma
14.05-14.30 Presenter 2 A. Kyriazoglou
Abstract 11516: Eribulin and gemcitabine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A multicenter, single-arm, phase 2-trial
Abstract 11520: High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes
Abstract 10005: Clinical impact of molecular tumor profiling in pediatric, adolescent and young adult patients with extra-cranial solid malignancies: An interim report from the GAIN/iCat2 study
14.30-14.50 Discussant I. Athanasiadis
Chairs: Ch. Papadimitriou, Α. Κοliadi
14.50-15.10 Presenter 1 M. Drizou
Abstract LBA3: Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase 3 OUTBACK Trial
(ANZGOG 0902, RTOG 1174, NRG 0274)
Abstract 5506: Intensive versus minimalist follow-up in patients treated for endometrial cancer: A multicentric randomized controlled trial (The TOTEM study - NCT00916708)
15.10-15.35 Presenter 2 G. Milaki
Abstract 5501: Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): A multicenter open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO (AGO-OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890)
Abstract 5502: Maintenance vigil immunotherapy in newly diagnosed advanced ovarian cancer: Efficacy assessment of homologous recombination proficient (HRP) patients in the phase IIb VITAL trial
Abstract 5504: Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis
15.35-15.55 Discussant M. Rovithi
Coffee Break
Chairs: P. Kosmidis, D. Ziogas
16.15-16.40 Presenter 1 D. Vassos
Abstract 8504: Video-assisted thoracoscopic versus open lobectomy in patients with early-stage lung cancer: One-year results from a randomized controlled trial (VIOLET)
Abstract 10506: Completion of lung cancer screening after a baseline order for LDCT at five diverse health systems
Abstract 8507: A randomized phase II trial of oral vinorelbine as second-line therapy for patients
with malignant pleural mesothelioma
16.40-17.00 Presenter 2 D. Stefanou
Abstract 8500: IMpower010: Primary results of a phase III global study of atezolizumab vs. best supportive care after adjuvant chemotherapy in resected Stage IB-IIIA non-small cell lung cancer (NSCLC)
Abstract 9000: First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA
17.00-17.20 Presenter 3 E. Biziota
Abstract 9006: Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed,
chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response
Abstract 9002: Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150
17.20-17.40 Discussant G. Oikonomopoulos
Chairs: K. Koutsoukos, G. Lainakis
17.40-18.00 Presenter 1 D. Matthaios
Abstract LBA5: Pembrolizumab versus placebo as post nephrectomy adjuvant therapy for patients with
renal cell carcinoma: Randomized, double-blind, phase 3 KEYNOTE-564 study
Abstract 4500: Final analysis of KEYNOTE-426: Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC)
18.00-18.25 Presenter 2 Th. Tegos
Abstract 4502: Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with
advanced renal cell carcinoma (aRCC)
Abstract 4509: Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial
Abstract 4520: Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial
18.25-18.45 Discussant E. Lianos
Chairs: Ch. Kourousis, M. Tsiatas
18.45-19.05 Presenter 1 I. Alafis
Abstract LBA4: Phase 3 study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION)
Abstract 5000: A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone
and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1
19.05-19.25 Presenter 2 Ν. Asimakopoulou
Abstract 5004: A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1
Abstract 5008: The CADMUS trial: A paired cohort, blinded study comparing multiparametric ultrasound targeted biopsies with multiparametric MRI targeted biopsies in the detection of clinically significant prostate cancer
19.25-19.45 Discussant K. Tsapakidis
Closing Remarks